Pfizer-KineMed Collaboration Extends to Target Novel Diabetes Pathways

  Pfizer-KineMedCollaborationExtendstoTargetNovelDiabetes Pathways  Business Wire  EMERYVILLE, Calif. -- March 27, 2013  KineMed Inc. (www.kinemed.com) today announced the renewal of a non-exclusive research collaboration with Pfizer Inc. (NYSE: PFE) for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes. The collaboration will employ KineMed’s unique dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.  Diabetes is an emerging global healthcare epidemic with an estimated 347 million people affected, according to the WHO. Diabetes is predicted to become the seventh leading cause of death in the world by the year 2030 and total deaths from diabetes are projected to rise by more than 50% in the next 10 years.  In the United States Type II diabetes affects over one quarter of Americans over the age of 65. Diabetes is a major cause of heart disease and stroke, and is now also the leading cause of kidney failure, non-traumatic lower-limb amputations and new cases of blindness among adults.  Despite 50 years of drug research, over 60% of patients remain unresponsive to current therapies, requiring novel approaches to address fundamental metabolic processes in diabetes.  “We are very pleased to announce the renewal of this ongoing partnership in an important area of medicine that affects so many Americans. Powerful discovery and investigative abilities of novel disease pathways are key strengths of our translational platform,” said Dr. Scott Turner, Executive Vice-President, R&D at KineMed. “We look forward to continuing to work with Pfizer to accelerate and rapidly de-risk the advancement of novel compounds in pre-clinical and clinical trials.”  About KineMed, Inc.  KineMed has created a broadly enabling proprietary technology that is potentially transformative in drug development and personalized medicine. Our Proteome Dynamics and Virtual Biopsy techniques provide a unique marriage of broad screening capacity (hypothesis-free “-omics” interrogation of living systems) with functional significance (translational interpretability). KineMed’s biomarkers are fully translational from animal to man, seamlessly harmonizing data across pre-clinical and clinical phases of development, through to the diagnosis and management of diseases including fibrotic, neurodegenerative, metabolic, cardiovascular disease and cancer.  KineMed has developed the first practically-useful systems biology technology that can be used directly in humans, with applications not only in drug discovery and development, but also in clinical diagnosis, personalized medicine and therapeutic monitoring. Over the past few years our advances in Proteome Dynamics and Virtual Biopsies have changed both textbook thought about diseases and the development path of several drug candidates. Notable accomplishments include:    *Developing a “tachometer” of reverse cholesterol transport and metrics of     plasma lipid dynamics   *Transforming the pathogenic model of chronic lymphocytic leukemia (CLL)   *Developing the first blood-based biomarker of tissue fibrogenesis in     humans   *Generating the first accurate laboratory biomarker of muscle mass in     humans   *Creating the first diagnostic tests of disease-modifying processes in a     neurodegenerative disease (Parkinson’s Disease)  For more information about KineMed, please visit: http://www.kinemed.com  Contact:  KineMed Inc. Ravi Kiron, Ph.D., MBA, Chief Business Officer Tel: 510-655-6525 ext. 105 Cell: 650-224-3836 rkiron@kinemed.com  
Press spacebar to pause and continue. Press esc to stop.